Literature DB >> 24751214

Beyond approval: what is the most appropriate way to use the expanding Armamentarium in metastatic castration-resistant prostate cancer and how do we move forward?

Daniel Suzman1, Mario Eisenberger2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24751214     DOI： 10.1016/j.eururo.2014.03.046

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


× No keyword cloud information.
  1 in total

1.  Phase I clinical trial of sipuleucel-T combined with escalating doses of ipilimumab in progressive metastatic castrate-resistant prostate cancer.

Authors:  Mark Scholz; Sabrina Yep; Micah Chancey; Colleen Kelly; Ken Chau; Jeffrey Turner; Richard Lam; Charles G Drake
Journal:  Immunotargets Ther       Date:  2017-03-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.